Product image of Mutaflor Mite (Escherichia Coli Strain Nissle 1917) supplied by GNH India

Mutaflor Mite

Active Ingredient:
Escherichia Coli Strain Nissle 1917
Origin:
EU

Mutaflor Mite (Escherichia Coli Strain Nissle 1917)

Escherichia coli Nissle 1917, the active ingredient in Mutaflor Mite, is a probiotic / live biotherapeutic presented as a lyophilised oral preparation for oral use. It is employed to support gastrointestinal health in conditions such as ulcerative colitis, inflammatory bowel disease and irritable bowel syndrome.

GNH India supplies Mutaflor Mite as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Manufacturer / TM Owner

Ardeypharm Gmbh

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

Mutaflor Mite is a probiotic that acts on the gastrointestinal tract to help manage inflammatory and functional bowel disorders.

  • Ulcerative colitis: assists in maintaining remission and reducing flare‑ups.
  • Inflammatory bowel disease: contributes to symptom control and mucosal barrier support.
  • Irritable bowel syndrome: may improve abdominal comfort and bowel regularity.

How It Works

  • Escherichia coli Nissle 1917 colonises the intestinal lumen, where it competes with pathogenic microbes for nutrients and adhesion sites, produces antimicrobial substances, and modulates host immune pathways. The strain enhances tight‑junction integrity, promotes regulatory T‑cell responses, and supports a balanced microbiota, collectively strengthening the intestinal barrier and reducing inflammatory signaling.

Side Effects

Adverse reactions are generally mild and related to gastrointestinal tolerance.

Common Side Effects

  • Bloating: transient abdominal distension.
  • Flatulence: increased gas production.
  • Abdominal discomfort: mild cramping or pain.
  • Mild diarrhoea: loose stools that resolve spontaneously.
  • Nausea: occasional feeling of queasiness.
  • Headache: low‑grade headache reported by some users.

Serious or Rare Side Effects

  • Sepsis: systemic infection, primarily in severely immunocompromised patients.
  • Bacteremia: presence of the strain in the bloodstream.
  • Severe allergic reaction: anaphylaxis or angioedema.
  • Persistent high‑grade fever: may indicate infection.
  • Gastrointestinal perforation: extremely rare but serious event.

Precautions & Warnings

Patients and prescribers should consider several safety measures before initiating therapy.

  • Immune status assessment: evaluate for severe immunodeficiency before use.
  • Antibiotic co‑administration: avoid concurrent broad‑spectrum antibiotics that may eradicate the probiotic.
  • Infection monitoring: watch for signs of systemic infection, especially in vulnerable individuals.
  • Pregnancy and lactation: use only if the benefit outweighs potential risk, as data are limited.
  • Medical supervision: ensure therapy is overseen by a qualified healthcare professional.
  • Store at ambient temperature: keep in the original pack, protect from moisture and direct sunlight.

Avoid Interactions

Probiotic therapy can be influenced by other medications and biologics.

Major Interactions (Avoid)

  • Broad‑spectrum antibiotics: may significantly reduce the viability of the probiotic strain.
  • Potent immunosuppressants: increase the risk of systemic infection from the live organism.

Moderate Interactions (Monitor Closely)

  • Other oral probiotics: concurrent use may alter colonisation dynamics.
  • Antifungal agents: could affect gut microbial balance and probiotic efficacy.
  • Live vaccines: consider timing to avoid potential interference with immune response.

Frequently Asked Questions

Mutaflor Mite is indicated for the maintenance of remission in ulcerative colitis, for overall management of inflammatory bowel disease, and as an adjunct to improve symptoms in irritable bowel syndrome. It works by modulating the gut microbiota and supporting intestinal barrier function.

The strain colonises the intestinal lumen, competes with harmful bacteria for nutrients and adhesion sites, produces antimicrobial compounds, and interacts with the host immune system to promote regulatory pathways. This helps restore a balanced microbiome and strengthens the gut barrier, reducing inflammation.

The specific dose and treatment schedule for Mutaflor Mite are determined by the prescribing clinician based on the patient’s condition, severity, and overall health status. Healthcare professionals tailor the regimen to achieve optimal therapeutic benefit.

Safety data for Mutaflor Mite in pregnancy and lactation are limited. It should only be used if the potential benefit justifies any possible risk to the mother or infant, and the decision must be made by a qualified healthcare provider.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Mutaflor Mite contains the well‑studied strain Escherichia coli Nissle 1917, which has demonstrated efficacy comparable to certain standard therapies for ulcerative colitis remission. Unlike many multi‑strain products, it offers a single, defined organism with a documented mechanism of action and clinical data supporting its use.

Mutaflor Mite should be stored at ambient temperature, below 25 °C, in its original packaging. Protect the product from moisture and direct sunlight to maintain bacterial viability until the point of use.

The product is taken orally, typically as a lyophilised powder that is reconstituted in water or a suitable liquid before ingestion. The exact administration instructions, including timing relative to meals, are provided by the prescribing clinician.

The most serious risks include rare cases of systemic infection such as sepsis or bacteremia, particularly in patients with severe immunosuppression. Anaphylactic reactions, though uncommon, may also occur and require immediate medical attention.

Mutaflor Mite is contraindicated in individuals with known hypersensitivity to Escherichia coli Nissle 1917 or any product excipients, and it should be avoided in patients with severe immunodeficiency or those receiving high‑dose immunosuppressive therapy unless specifically advised by a physician.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.